Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. LFMD
LFMD logo

LFMD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy LifeMD Inc (LFMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
4.750
1 Day change
-3.26%
52 Week Range
15.840
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

LifeMD Inc (LFMD) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock has shown a negative price trend in the short term, with no significant positive catalysts or trading signals to suggest an immediate entry point. While the technical indicators show mixed signals, the lack of strong financial data, news, or institutional interest does not support a compelling case for investment right now.

Technical Analysis

The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 46.585, suggesting no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below key pivot support levels, with S1 at 4.666 and the current price at 4.6849. This suggests limited upside potential in the short term.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low put-call ratios indicate a bullish sentiment in the options market, but the overall volume and open interest data are not significant enough to drive a strong directional bias.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
5

Positive Catalysts

  • Bullish moving averages and low put-call ratios in the options market suggest some underlying support for the stock.

Neutral/Negative Catalysts

  • The stock has shown a consistent decline in price (-3.26% regular market change, -1.37% post-market change). No recent news, financial data, or trading activity from insiders, hedge funds, or Congress to act as a catalyst. Technical indicators like MACD and RSI are not signaling a strong buy opportunity.

Financial Performance

No financial data available for analysis. The latest quarter's performance could not be assessed.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on analyst ratings or price target changes is available for LFMD at this time.

Wall Street analysts forecast LFMD stock price to rise
7 Analyst Rating
Wall Street analysts forecast LFMD stock price to rise
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.910
sliders
Low
6
Averages
9.67
High
15
Current: 4.910
sliders
Low
6
Averages
9.67
High
15
Mizuho
Neutral -> Outperform
upgrade
$6 -> $8
AI Analysis
2026-03-16
Reason
Mizuho
Price Target
$6 -> $8
AI Analysis
2026-03-16
upgrade
Neutral -> Outperform
Reason
Mizuho upgraded LifeMD to Outperform from Neutral with a price target of $8, up from $6. The firm cites the company's better than expected 2026 outlook for the upgrade. LifeMD continues to expand into new therapeutic areas for virtual care, but the investment thesis is still riven by the company's weight loss management program, the analyst tells investors in a research note. Mizuho sees the company's oral GLP-1 drugs "serving as the anchor" to drive patient growth in 2026 and beyond. It views LifeMD as a "portfolio" play on branded GLP-1s from both Eli Lilly and Novo Nordisk, "without having to decide which manufacturer will be the winner."
Freedom Capital
Buy
upgrade
$8 -> $10
2026-03-12
Reason
Freedom Capital
Price Target
$8 -> $10
2026-03-12
upgrade
Buy
Reason
Freedom Capital raised the firm's price target on LifeMD to $10 from $8 and keeps a Buy rating on the shares. The company's Q4 reported confirm a growth reacceleration as its revenue and adjusted EBITDA beat expectations, the analyst tells investors in a research note. The firm sees share upside from LifeMD's user-retention metrics.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for LFMD
Unlock Now

People Also Watch